Welcome!

News Feed Item

European Researchers Invited to Submit Study Proposals for Bristol-Myers Squibb's Partnering for Cure™ Virology Research Programme

PARIS, April 8, 2014 /PRNewswire/ --

Partnering for Cure is Bristol-Myers Squibb's flagship, Pan-European scientific initiative supporting breakthrough research and facilitating greater collaboration and knowledge-sharing with the virology community 

In advance of this year's International Liver CongressTM 2014 in London, England, Bristol-Myers Squibb invites European researchers to submit innovative research ideas that aim to cure chronic virological diseases. As part of Bristol-Myers Squibb's ongoing commitment in virology, these projects provide an opportunity for researchers, particularly junior faculty and young investigators, to accelerate novel solutions that could lead to cures in HIV, hepatitis B (HBV) and hepatitis C (HCV).

This latest round of research applications will be accepted from 1 May to 15 July 2014 and aspiring scientists are encouraged to submit their ideas at http://www.bms.com/israpplications. Priority will be given to research proposals in the area of translational science with a clear relevance for the clinical development of a cure in viral hepatitis or HIV infection.

Partnering for Cure is led by the Partnering for CureFaculty, an expert panel of clinical and research experts from across Europe and focuses on three pillars - education, scientific exchange and scientific research. The Faculty will award up to four recipients in a blinded evaluation after applications close. The four research applicants will share between them just over €300,000 in support from Bristol-Myers Squibb.

"This year, we were proud to announce our first class of Partnering for Cureresearch programme recipients in January," said Professor Jürgen Rockstroh, Partnering for Cure Faculty Chair. "Now we're looking for even more proposals to expand our clinical network and continuing the fight against chronic viral diseases through the 2014 Partnering for Cure research programme."  

Matthieu Perreau, Centre Hospitalier Universitaire Vaudois (CHUV) Service Immunologie et Allergie, Switzerland, was one of the four Partnering for Cure research programme recipients last year, awarded for his research, Identification of the memory CD4 T-cell population(s) harbouring replication competent HIV-1 within lymphoid tissues.

"This grant has provided me with the opportunity to pursue my passion and make an impact in the virology community," remarks Perreau. "It is an honour to be part of this exciting initiative, and I look forward to working with my research colleagues to find a cure."

"Bristol-Myers Squibb has a longstanding vision of continuing to transform the treatment of viral diseases and fulfilling serious unmet medical needs of patients," said George Hanna, MD, vice president, HIV Development, Bristol-Myers Squibb. "We look forward to this year's applications and supporting the upcoming generation of researchers and scientists who are dedicated to improving treatments and delivering true advances in patient care."

The projects that will receive support from Bristol-Myers Squibb will be announced on World AIDS Day - 1 December 2014.

About Partnering for Cure 

Partnering for Cure is a European medical education programme developed as part of Bristol-Myers Squibb's ongoing commitment to virology research, education and transforming clinical outcomes for patients with chronic viral diseases. The programme focuses on recent and ongoing cure research in HIV, HBV and HCV.

The objectives of the programme are to:

  • Provide medical education to physicians interested in virology cure research
  • Provide support to researchers active in virology cure research
  • Provide a forum for physicians and researchers to discuss advances in virology cure

The Partnering for Cure initiative reinforces Bristol-Myers Squibb's commitment in virology, which is rooted in the company's legacy in virology and ongoing research in HIV and viral hepatitis. Chronic viral infections make a substantial contribution to the burden of chronic diseases and premature mortality worldwide. In December 2012, the Global Burden of Disease Study reported 1,465,000 deaths caused by HIV/AIDS and 1,445,000 deaths caused by viral hepatitis in 2010.[i] Infections with hepatitis B and C viruses also cause an estimated 57 percent of cases of liver cirrhosis and 78 percent of cases of primary liver cancer annually.[ii] Whilst important advances have been made over the last decade significant unmet needs and the opportunity for cure remains, particularly in HIV.

Bristol-Myers Squibb's Commitment to Virology 

For over 20 years, Bristol-Myers Squibb has worked collaboratively with the virology community to help meet the needs of patients living with HIV, HBV and HCV - by providing and developing medicines such as Zerit®, Videx®, Sustiva®, Atripla[®*], Reyataz®, Baraclude®, supporting clinical research on new innovative compounds, supporting disease education efforts, and improving access to medicines in the developing world.

Bristol-Myers Squibb supports a number of scientific and educational programs within the virology community around the world that encompass disease education, disease awareness and sharing of best practices. In addition to Partnering for Cure these include SHE® (Strong, HIV positive, Empowered Women/Strong, HIV positive Women Educational Programme), a comprehensive and innovative programme for women living with HIV and their healthcare providers, PATH B® (Patients and professionals acting together for hepatitis B), a joint initiative between hepatitis patient groups and hepatologists to provide comprehensive information and support for patients with chronic hepatitis B.

Additionally, Bristol-Myers Squibb Foundation's philanthropic and educational programmes, such as Secure the Future® and Delivering Hope® aim to support people living with HIV in Africa and with viral hepatitis in Asia, through numerous private-public partnerships and community based projects.

VIRUK14NP01991-01

Prepared April 2014

* Atripla® is a trademark of Bristol-Myers Squibb Co. and Gilead Sciences, Inc.

i. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010, The Lancet, Volume 380, No9859, Dec 15, 2012 pp2095-2128

ii. WHO and WHA, Global Policy Report on the Prevention and Control of Viral Hepatitis, 2013, http://global-report.worldhepatitisalliance.org/en/home.html


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Providing the needed data for application development and testing is a huge headache for most organizations. The problems are often the same across companies - speed, quality, cost, and control. Provisioning data can take days or weeks, every time a refresh is required. Using dummy data leads to quality problems. Creating physical copies of large data sets and sending them to distributed teams of developers eats up expensive storage and bandwidth resources. And, all of these copies proliferating...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
SYS-CON Events announced today that Technologic Systems Inc., an embedded systems solutions company, will exhibit at SYS-CON's @ThingsExpo, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Technologic Systems is an embedded systems company with headquarters in Fountain Hills, Arizona. They have been in business for 32 years, helping more than 8,000 OEM customers and building over a hundred COTS products that have never been discontinued. Technologic Systems’ pr...
SYS-CON Events announced today that CA Technologies has been named “Platinum Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business – from apparel to energy – is being rewritten by software. From ...
The taxi industry never saw Uber coming. Startups are a threat to incumbents like never before, and a major enabler for startups is that they are instantly “cloud ready.” If innovation moves at the pace of IT, then your company is in trouble. Why? Because your data center will not keep up with frenetic pace AWS, Microsoft and Google are rolling out new capabilities In his session at 20th Cloud Expo, Don Browning, VP of Cloud Architecture at Turner, will posit that disruption is inevitable for c...
SYS-CON Events announced today that Cloudistics, an on-premises cloud computing company, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Cloudistics delivers a complete public cloud experience with composable on-premises infrastructures to medium and large enterprises. Its software-defined technology natively converges network, storage, compute, virtualization, and management into a ...
Deep learning has been very successful in social sciences and specially areas where there is a lot of data. Trading is another field that can be viewed as social science with a lot of data. With the advent of Deep Learning and Big Data technologies for efficient computation, we are finally able to use the same methods in investment management as we would in face recognition or in making chat-bots. In his session at 20th Cloud Expo, Gaurav Chakravorty, co-founder and Head of Strategy Development ...
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor - all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
What if you could build a web application that could support true web-scale traffic without having to ever provision or manage a single server? Sounds magical, and it is! In his session at 20th Cloud Expo, Chris Munns, Senior Developer Advocate for Serverless Applications at Amazon Web Services, will show how to build a serverless website that scales automatically using services like AWS Lambda, Amazon API Gateway, and Amazon S3. We will review several frameworks that can help you build serverle...
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
SYS-CON Events announced today that Loom Systems will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Founded in 2015, Loom Systems delivers an advanced AI solution to predict and prevent problems in the digital business. Loom stands alone in the industry as an AI analysis platform requiring no prior math knowledge from operators, leveraging the existing staff to succeed in the digital era. With offices in S...
SYS-CON Events announced today that Interoute, owner-operator of one of Europe's largest networks and a global cloud services platform, has been named “Bronze Sponsor” of SYS-CON's 20th Cloud Expo, which will take place on June 6-8, 2017 at the Javits Center in New York, New York. Interoute is the owner-operator of one of Europe's largest networks and a global cloud services platform which encompasses 12 data centers, 14 virtual data centers and 31 colocation centers, with connections to 195 add...
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
Interoute has announced the integration of its Global Cloud Infrastructure platform with Rancher Labs’ container management platform, Rancher. This approach enables enterprises to accelerate their digital transformation and infrastructure investments. Matthew Finnie, Interoute CTO commented “Enterprises developing and building apps in the cloud and those on a path to Digital Transformation need Digital ICT Infrastructure that allows them to build, test and deploy faster than ever before. The int...
SYS-CON Events announced today that CrowdReviews.com has been named “Media Sponsor” of SYS-CON's 20th International Cloud Expo, which will take place on June 6–8, 2017, at the Javits Center in New York City, NY. CrowdReviews.com is a transparent online platform for determining which products and services are the best based on the opinion of the crowd. The crowd consists of Internet users that have experienced products and services first-hand and have an interest in letting other potential buyers...